Phase 2 N=55 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Brain and Central Nervous System Tumors
Primary: Proportion of Participants With Objective Response Rate (ORR) — 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma
CNS Cancer · CNS BRAIN
Primary: Progession Free Survival — 85.7 % of participants without progression
Phase 3 N=230 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Brain and Central Nervous System Tumors
Primary: (Phase III) Overall Survival (OS) — 3.9; 3.8 years — p=0.36
Phase 2 N=19 Antineoplaston Therapy in Treating Adult Patients With Anaplastic Astrocytoma
Adult Brain Tumor
Primary: Number of Participants With Objective Response — 3; 1; 5; 9 Participants
Phase 2 N=74 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
Anaplastic Glioma of Brain · Glioblastoma Multiforme · Brain Cancer
Primary: 12 Month-progression-free Survival for Participants With Anaplastic Tumors — 44 percentage of participants
Phase 2 N=45 Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: PFS-6 — 1; 8 Participants
Phase 2 N=31 Low Dose Radiation Therapy for Glioblastoma Multiforme
High Grade Glioma
Primary: Response Rate
Phase 2 N=27 Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
Anaplastic Astrocytoma
Primary: Number of Participants With Objective Response — 2; 3; 6; 10 Participants
Phase 2 N=40 Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme
Glioblastoma Multiforme of the Brain
Primary: Number of Participants With Objective Response — 1; 1; 5; 19 Participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Newly-diagnosed Glioblastoma Multiforme
Glioblastoma Multiforme of Brain
Primary: Number of Participants With Objective Response — 2; 1; 2; 27 Participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Brain Stem Glioma
Brain Stem Gliomas
Primary: Number of Participants With Objective Response — 5; 4; 8; 14 Participants
Phase 2 N=20 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Anaplastic Astrocytomas · Anaplastic Oligodendrogliomas · Glioblastomas (GBM)
Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants
Phase 2 N=20 Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
Mixed Gliomas
Primary: Number of Participants With Objective Response — 3; 0; 4; 10 Participants
N/A N=1 Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma
Astrocytoma, Grade III
Primary: Number of Participants Showing no Evidence of Disease Progression Six Months After Initiating Treatment With the Device. — 1 Participants
Phase 2 N=30 A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
Anaplastic Astrocytoma · Glioblastoma
Primary: Number of Participants With Progression Free Survival (PFS) at 6 Months Utilizing McDonald Criteria for Response, Progression and Relapse — 4; 2; 2 Participants
Phase 2 N=151 A Study in Subjects With Recurrent Malignant Glioma
Glioma
Primary: Progression Free Survival (PFS) Rate at Month 6 — 11.0; 21.2; 8.0; 7.6 Percentage of participants
Phase 1 N=9 Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Astrocytoma
Glioblastoma Multiforme/Anaplastic Astrocytoma
Primary: Maximum Tolerated Dose(MTD)of Temozolomide(TMZ) — 75 mg/m^2
Phase 2 N=41 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Glioblastoma Multiforme · Gliosarcoma
Primary: Response Rate — 22 percentage of participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Malignant Brain Tumors
Primary: Number of Participants With Objective Response — 2; 2; 4; 19 Participants
Phase 2 N=58 VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Progression-free Survival (PFS) at 6 Months — 25; 7.7 percentage of participants
Phase 2 N=120 Temozolomide in Treating Patients With Low-Grade Glioma
CNS Tumor, Adult
Primary: Response Rate (Complete and Partial Response) — 7 Participants
Phase 1 N=16 Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
Adult Anaplastic Astrocytoma · Adult Anaplastic Oligodendroglioma · Adult Giant Cell Glioblastoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) — 0; 0; 0; 1 Participants
Phase 2 N=10 Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma
MGMT-unmethylated Glioblastoma (GBM) · GBM
Primary: 1-year Overall Survival (OS) — 80 percentage of participants
Phase 2 N=5 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma
Adult Diffuse Astrocytoma · Adult Mixed Glioma · Adult Oligodendroglioma
Primary: Progression-free Survival (PFS) of Low Grade Glioma Patients Treated With Autologous Dendritic Cells Pulsed With Autologous Tumor Lysate — 0; 1; 1; 1 participants
Phase 2 N=40 Antineoplaston Therapy in Treating Patients With Brain Tumors
Refractory Brain Tumors
Primary: Number of Participants With Objective Response — 4; 5; 12; 10 Participants
Phase 2 N=17 Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Glioblastoma · Glioblastoma With Primitive Neuronal Component · Gliosarcoma
Primary: Proportion of Progression Free Survival Participants (PFS) at Six Months — 0.786 Proportion of participants
Phase 1 N=3 Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma
Glioma · Anaplastic Astrocytoma · Anaplastic Oligodendroglioma
Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities
Phase 2 N=72 Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
Glioblastoma
Primary: Safety, Tolerability, and Feasibility of Combination Intra-operative 5-ALA and Gliadel Wafers Prior to Adjuvant Radiotherapy Plus Temozolomide — 62; 9; 6; 45 Participants
N/A N=11 Image-Guided Stereotactic Biopsy of High Grade Gliomas
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Phase 2 N=53 A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants